New hope for chinese men with tough prostate cancer: targeted drug takes on standard care

NCT ID NCT05457257

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares the targeted drug olaparib to two standard hormone therapies (enzalutamide or abiraterone) in Chinese men with advanced prostate cancer that has stopped responding to hormone treatment and who have BRCA1/2 gene mutations. The goal is to see if olaparib can delay cancer growth better than the usual options. About 43 men will participate, and the study tracks how long their cancer stays under control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Research Site

Beijing, 100050, China
Research Site

Bengbu, 233004, China
Research Site

Changsha, 410008, China
Research Site

Changsha, 410013, China
Research Site

Chengdu, 610000, China
Research Site

Chongqing, 408099, China
Research Site

Fuzhou, 350005, China
Research Site

Guangzhou, 510060, China
Research Site

Guangzhou, 510180, China
Research Site

Hangzhou, 310003, China
Research Site

Hangzhou, 310009, China
Research Site

Hangzhou, 310014, China
Research Site

Hefei, 230601, China
Research Site

Jiaxing, 314001, China
Research Site

Jinan, 250012, China
Research Site

Jinan, 250021, China
Research Site

Jining, 272029, China
Research Site

Kunming, 650101, China
Research Site

Lanzhou, 730030, China
Research Site

Linyi, 276000, China
Research Site

Nanchang, 330006, China
Research Site

Nantong, 226361, China
Research Site

Ningbo, 315010, China
Research Site

Shanghai, 200002, China
Research Site

Shanghai, 200032, China
Research Site

Shenyang, 110004, China
Research Site

Suzhou, 215004, China
Research Site

Taiyuan, 030000, China
Research Site

Tianjin, 300060, China
Research Site

Wanzhou, 404000, China
Research Site

Wuhan, 430022, China
Research Site

Wuxi, 214002, China
Research Site

Wuxi, 214023, China
Research Site

Xi'an, 710077, China
Research Site

Zhengzhou, 450052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.